Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.

ABSTRACT:

Background

For older adults with relapsing-onset multiple sclerosis (MS), limited information is available to inform if, or when, disease-modifying drugs (DMDs) may be safely discontinued.

Objective

The aim of this study was to project the outcomes of DMD discontinuation among older adults with relapsing-onset MS.

Methods

We projected the 10-year outcomes of discontinuation of a DMD (interferon-β, fingolimod, or natalizumab) among older adults (aged 55 or 70 years) who were relapse-free for 5 or more years and had not reached an Expanded Disability Status Scale (EDSS) score of 6. Outcomes included the percentage of people who had at least one relapse or reached EDSS 6, and quality-adjusted life-years (QALYs), which incorporated both relapses and disability. We used a

SUBMITTER: Schwehr NA 

PROVIDER: S-EPMC7047543 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature